Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Pipeline Review, H2 2017

  • ID: 4426905
  • Report
  • 78 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Biogen Inc
  • BioMAS Ltd
  • Factor Therapeutics Ltd
  • MedImmune LLC
  • Merck & Co Inc
  • Merck KGaA
  • MORE
Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Pipeline Review, H2 2017

Summary

Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Integrin alpha-V is a protein encoded by the ITGAV gene. Alpha-V integrins are receptors for vitronectin, cytotactin, fibronectin, fibrinogen, laminin, matrix metalloproteinase-2, osteopontin, osteomodulin, prothrombin, thrombospondin and vWF. The encoded preproprotein is proteolytically processed to generate light and heavy chains that comprise the alpha V subunit. This subunit associates with beta 1, beta 3, beta 5, beta 6 and beta 8 subunits. The heterodimer consisting of alpha V and beta 3 subunits is also known as the vitronectin receptor. This integrin regulate angiogenesis and cancer progression.

Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) pipeline Target constitutes close to 25 molecules. Out of which approximately 19 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II and Preclinical stages are 6 and 13 respectively. Similarly, the universities portfolio in Preclinical stages comprises 6 molecules, respectively. Report covers products from therapy areas Oncology, Metabolic Disorders, Ophthalmology, Respiratory, Gastrointestinal, Infectious Disease, Musculoskeletal Disorders, Cardiovascular, Dermatology, Genito Urinary System And Sex Hormones and Toxicology which include indications Wet (Neovascular / Exudative) Macular Degeneration, Breast Cancer, Idiopathic Pulmonary Fibrosis, Diabetic Nephropathy, Diabetic Retinopathy, Fibrosis, Glioblastoma Multiforme (GBM), Liver Fibrosis, Pancreatic Cancer, Age Related Macular Degeneration, Cardiovascular Disease, Chemotherapy Effects, Diabetic Macular Edema, Genital Warts (Condylomata Acuminata), Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease), Kidney Fibrosis, Malabsorption Syndrome, Melanoma, Metastatic Melanoma, Multiple Myeloma (Kahler Disease), Retinal Vein Occlusion, Sepsis and Venous Leg Ulcers (Crural ulcer).

The latest report Integrin Alpha V - Pipeline Review, H2 2017, outlays comprehensive information on the Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV)
  • The report reviews Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) targeted therapeutics.
Reasons to Buy:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Biogen Inc
  • BioMAS Ltd
  • Factor Therapeutics Ltd
  • MedImmune LLC
  • Merck & Co Inc
  • Merck KGaA
  • MORE
Introduction

Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Overview

Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Companies Involved in Therapeutics Development

Biogen Inc

BioMAS Ltd

Factor Therapeutics Ltd

MedImmune LLC

Merck & Co Inc

Merck KGaA

Morphic Therapeutic Inc

SciFluor Life Sciences LLC

Vascular Pharmaceuticals Inc

Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Drug Profiles

264-RAD - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

abituzumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AC-301 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antibodies to Integrin Inhibit Alpha V and Beta 6 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AS-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BG-00011 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

C-16Y - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cilengitide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CWHM-12 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MK-0429 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MSP-68 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OCU-200 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptides to Antagonize Alpha-V Beta-3 Integrin Receptor for Melanoma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Proagio - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Protein to Agonize Integrin Alpha V, Beta 3 and Beta 5 for Malabsorption Syndrome - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein to Antagonize VEGFR2, ITGB3 and ITGAV for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RSF-201 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SF-0166 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize AlphaV and Beta6 for Fibrosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize Integrin Alpha V and Beta 1 for Cardiovascular Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize Integrin Alpha V for Fibrosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize Integrin Alpha V for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tetraiodothyroacetic acid - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VF-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VPI-2690B - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Dormant Products

Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Discontinued Products

Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Product Development Milestones

Featured News & Press Releases

Nov 02, 2017: VF001002 Clinical Trial Update: Strong performance in October driven by new sites

Oct 20, 2017: Pursuing Novel Pathways in Immunology: Merck Presents New Clinical Data on Abituzumab at 2017 ACR/ARHP Annual Meeting

Sep 28, 2017: SciFluor Announces Positive Results of Phase 1/2 Study of SF0166 Topical Ophthalmic Solution in Diabetic Macular Edema Patients

May 08, 2017: Ocugen Expands Global Patent Portfolio for OCU200

Apr 07, 2017: Factor Therapeutics: Phase II Clinical Trial Progress Update

Dec 20, 2016: Factor Therapeutics - First Patient In and Clinical Update

Nov 07, 2016: FDA Clinical Hold Lifted for IND 119526 (VF - 001)

Oct 17, 2016: SciFluor Life Sciences Announces First Patients Dosed in Retinal Program with Investigational New Drug Application for SF0166 Topical Ophthalmic Solution

Oct 10, 2016: Submission of IND Amendments for Phase II Study of VF - 001 in the US

Aug 03, 2016: Factor Therapeutics Announces Formation of Medical Advisory Board

Aug 01, 2016: SciFluor Life Sciences Enters Clinical Trial Stage for Novel Treatment for Retinal Diseases

May 31, 2016: New Class of Protein Could Treat Cancer and Other Diseases, Georgia State Researchers Find

May 25, 2016: Iceni Pharmaceuticals launches as new company focusing on repurposing therapies in the field of oncology

Apr 02, 2016: Iceni Pharmaceuticals announces appointment of cilengitide inventor Prof. Dr. Horst Kessler to its Scientific Advisory Board

Mar 09, 2016: SciFluor Life Sciences Awarded Second U.S. Patent for Integrin avß3 (SF0166) Inhibitors Designed for the Topical Treatment of Retinal Disease

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Therapy Areas, H2 2017

Number of Products under Development by Indications, H2 2017

Number of Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017

Number of Products under Investigation by Universities/Institutes, H2 2017

Products under Investigation by Universities/Institutes, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Pipeline by Biogen Inc, H2 2017

Pipeline by BioMAS Ltd, H2 2017

Pipeline by Factor Therapeutics Ltd, H2 2017

Pipeline by MedImmune LLC, H2 2017

Pipeline by Merck & Co Inc, H2 2017

Pipeline by Merck KGaA, H2 2017

Pipeline by Morphic Therapeutic Inc, H2 2017

Pipeline by SciFluor Life Sciences LLC, H2 2017

Pipeline by Vascular Pharmaceuticals Inc, H2 2017

Dormant Products, H2 2017

Discontinued Products, H2 2017

List of Figures

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Therapy Areas, H2 2017

Number of Products under Development by Top 10 Indications, H2 2017

Number of Products by Mechanism of Actions, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Biogen Inc
  • BioMAS Ltd
  • Factor Therapeutics Ltd
  • MedImmune LLC
  • Merck & Co Inc
  • Merck KGaA
  • Morphic Therapeutic Inc
  • SciFluor Life Sciences LLC
  • Vascular Pharmaceuticals Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll